Teva
Teva collaborates on skin disease treatment, releases targets
Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a phase 1b trial for the treatment of vitiligo
Teva seeks startups to help solve global pharmaceutical challenges
Placing the focus on the therapist
Does a common heart attack pill help everyone? Studies disagree
Teva collaborates with Technion in fields of cancer, neurobiology
Teva has already initiated collaborations with leading academic institutions, including Tel Aviv University, the Weizmann Institute of Science, and more.
Israeli researchers provide evidence microdosing cannabis relieves pain
The researchers published their findings in the European Journal of Pain, providing the first scientific evidence that microdosing can be applied medical cannabis solution.
Teva Israel sues Abbott over baby formula
Teva is claiming that Abbott Israel, a local entity which imports Similac, is behind a “mendacious and covert slur campaign” on social media.
Teva Naot opens fourth branch in Japan
Teva Naot markets about 100 different models of Japanese women’s fashion shoes.
Florida has not distributed most of hydroxychloroquine doses from Israel
Only a handful of hospitals have requested access to the hydroxychloroquine stockpile, according to the report.
Teva gets approval in China for Huntington's disease treatment
Teva’s CEO Kare Schultz said the drug would be priced somewhat lower in China than in the United States.
Teva's profit beats forecasts, shares jump
Shares in the world’s largest generic drugmaker jumped nearly 20% in late Tel Aviv trade as the company also reaffirmed its 2020 outlook, despite disruption to the global economy from the coronavirus
Teva donates potential coronavirus treatment to hospitals across the US
Hydroxychloroquine sulfate tablets are used against malaria, lupus erythematosus and rheumatoid arthritis but could be effective against COVID-19.
After turbulent years, Teva CEO Schultz forecasts stability
Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.
Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv
Researcher Hila Flayev has for years been conducting research on computational models of the coronavirus structure and interactions it can create.